2,513 Shares in Elanco Animal Health Incorporated (NYSE:ELAN) Purchased by Jones Financial Companies Lllp

Jones Financial Companies Lllp bought a new stake in shares of Elanco Animal Health Incorporated (NYSE:ELANFree Report) in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 2,513 shares of the company’s stock, valued at approximately $37,000.

Several other large investors have also recently made changes to their positions in the business. Primecap Management Co. CA grew its position in Elanco Animal Health by 2.9% during the 4th quarter. Primecap Management Co. CA now owns 50,600,324 shares of the company’s stock valued at $753,945,000 after purchasing an additional 1,431,665 shares during the last quarter. Vanguard Group Inc. raised its stake in shares of Elanco Animal Health by 0.7% in the third quarter. Vanguard Group Inc. now owns 49,001,441 shares of the company’s stock worth $550,776,000 after purchasing an additional 362,152 shares during the last quarter. Black Creek Investment Management Inc. raised its stake in shares of Elanco Animal Health by 12.8% in the third quarter. Black Creek Investment Management Inc. now owns 15,523,457 shares of the company’s stock worth $174,484,000 after purchasing an additional 1,759,556 shares during the last quarter. Dimensional Fund Advisors LP lifted its holdings in shares of Elanco Animal Health by 33.8% during the fourth quarter. Dimensional Fund Advisors LP now owns 15,095,179 shares of the company’s stock valued at $224,920,000 after purchasing an additional 3,816,514 shares in the last quarter. Finally, The Manufacturers Life Insurance Company boosted its position in shares of Elanco Animal Health by 7.6% during the third quarter. The Manufacturers Life Insurance Company now owns 5,003,011 shares of the company’s stock valued at $56,234,000 after buying an additional 354,524 shares during the last quarter. 97.48% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In related news, Director William F. Doyle bought 15,000 shares of the company’s stock in a transaction that occurred on Tuesday, May 21st. The stock was purchased at an average price of $16.98 per share, for a total transaction of $254,700.00. Following the completion of the transaction, the director now owns 76,330 shares in the company, valued at $1,296,083.40. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. 0.57% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

Several research firms have issued reports on ELAN. Barclays upped their target price on shares of Elanco Animal Health from $19.00 to $23.00 and gave the company an “overweight” rating in a research note on Thursday, May 9th. Piper Sandler restated a “neutral” rating and set a $19.00 price objective (up previously from $18.00) on shares of Elanco Animal Health in a research report on Monday, May 13th. Morgan Stanley lifted their target price on shares of Elanco Animal Health from $16.00 to $17.00 and gave the stock an “overweight” rating in a research report on Tuesday, February 27th. TheStreet raised Elanco Animal Health from a “d+” rating to a “c-” rating in a report on Friday, February 23rd. Finally, The Goldman Sachs Group lifted their price objective on Elanco Animal Health from $12.50 to $14.00 and gave the stock a “sell” rating in a report on Tuesday, February 27th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and five have given a buy rating to the stock. According to data from MarketBeat.com, Elanco Animal Health presently has a consensus rating of “Moderate Buy” and a consensus target price of $18.29.

View Our Latest Research Report on ELAN

Elanco Animal Health Trading Down 1.0 %

NYSE:ELAN opened at $18.27 on Friday. The business has a fifty day moving average price of $15.47 and a 200-day moving average price of $15.06. The company has a debt-to-equity ratio of 0.95, a current ratio of 3.29 and a quick ratio of 1.96. Elanco Animal Health Incorporated has a one year low of $8.52 and a one year high of $18.65. The firm has a market capitalization of $9.03 billion, a price-to-earnings ratio of -6.89, a price-to-earnings-growth ratio of 1.76 and a beta of 1.45.

Elanco Animal Health (NYSE:ELANGet Free Report) last announced its quarterly earnings data on Wednesday, May 8th. The company reported $0.34 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.26 by $0.08. Elanco Animal Health had a negative net margin of 29.83% and a positive return on equity of 5.98%. The firm had revenue of $1.21 billion during the quarter, compared to analysts’ expectations of $1.18 billion. During the same period in the prior year, the company posted $0.45 earnings per share. The company’s revenue for the quarter was down 4.1% compared to the same quarter last year. Sell-side analysts forecast that Elanco Animal Health Incorporated will post 0.93 EPS for the current year.

Elanco Animal Health Profile

(Free Report)

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.

See Also

Institutional Ownership by Quarter for Elanco Animal Health (NYSE:ELAN)

Receive News & Ratings for Elanco Animal Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Elanco Animal Health and related companies with MarketBeat.com's FREE daily email newsletter.